USANA Health Sciences (NYSE:USNA) Issues Q3 2025 Earnings Guidance

Key Points

• USANA Health Sciences has issued Q3 2025 earnings guidance, projecting a loss of $0.15 per share, significantly lower than the analyst consensus of $0.47 per share.
• The company also anticipates revenue of $214 million, falling short of the $224.1 million consensus estimate.
• USANA's shares declined by 1.0%, closing at $26.24, as analysts have recently downgraded the stock to a "hold" rating with a consensus price target of $36.00.

USANA Health Sciences (NYSE:USNA - Get Free Report) issued an update on its third quarter 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of -0.150--0.150 for the period, compared to the consensus earnings per share estimate of 0.470. The company issued revenue guidance of $214.0 million-$214.0 million, compared to the consensus revenue estimate of $224.1 million.

USANA Health Sciences Trading Down 1.0%

Shares of USANA Health Sciences stock traded down $0.27 during trading on Thursday, hitting $26.24. 111,891 shares of the stock traded hands, compared to its average volume of 168,630. The firm has a market cap of $479.44 million, a P/E ratio of 14.58, a price-to-earnings-growth ratio of 0.84 and a beta of 0.61. USANA Health Sciences has a 52-week low of $23.10 and a 52-week high of $41.83. The stock's fifty day simple moving average is $29.87 and its 200 day simple moving average is $29.34.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The company reported $0.74 EPS for the quarter, topping analysts' consensus estimates of $0.54 by $0.20. The company had revenue of $235.85 million during the quarter, compared to analysts' expectations of $225.20 million. USANA Health Sciences had a return on equity of 9.48% and a net margin of 3.79%. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. As a group, equities analysts expect that USANA Health Sciences will post 2.45 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on USNA shares. Zacks Research lowered shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 22nd. Weiss Ratings reissued a "sell (d+)" rating on shares of USANA Health Sciences in a research note on Wednesday. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, USANA Health Sciences has a consensus rating of "Reduce" and a consensus price target of $36.00.

Insider Transactions at USANA Health Sciences

In related news, Director Gilbert A. Fuller sold 1,058 shares of USANA Health Sciences stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $29.10, for a total value of $30,787.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider David Mulham Mulham sold 3,515 shares of the company's stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $30.26, for a total transaction of $106,363.90. Following the completion of the transaction, the insider owned 9,260 shares in the company, valued at approximately $280,207.60. This represents a 27.51% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.63% of the company's stock.

Institutional Trading of USANA Health Sciences

Large investors have recently bought and sold shares of the stock. Lazard Asset Management LLC grew its holdings in USANA Health Sciences by 130.3% during the second quarter. Lazard Asset Management LLC now owns 23,201 shares of the company's stock valued at $708,000 after purchasing an additional 13,128 shares during the period. Empowered Funds LLC acquired a new position in USANA Health Sciences during the first quarter valued at approximately $687,000. AQR Capital Management LLC lifted its stake in USANA Health Sciences by 82.8% in the first quarter. AQR Capital Management LLC now owns 21,845 shares of the company's stock valued at $589,000 after acquiring an additional 9,894 shares during the last quarter. Tidal Investments LLC increased its position in USANA Health Sciences by 45.9% during the second quarter. Tidal Investments LLC now owns 16,906 shares of the company's stock worth $516,000 after buying an additional 5,318 shares during the last quarter. Finally, Vident Advisory LLC bought a new position in shares of USANA Health Sciences in the second quarter valued at about $437,000. 54.25% of the stock is currently owned by institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.